TVRD Stock Analysis: Buy, Sell, or Hold?
TVRD - Tvardi Therapeutics, Inc. Common Stock
$1.50
-0.86 (-36.44%)
▼
5d:
-42.97%
30d:
-54.55%
90d:
-54.95%
WAIT
LOW Confidence
Analysis Updated: Jun 26, 2026 12:00 AM ET
Earnings: Aug 13, 2026
Get Alerted When TVRD Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: TVRD is down 43.0% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: TVRD is down 43.0% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: TVRD is currently trading at $1.50, which is considered oversold relative to its 30-day fair value range of $2.42 to $3.44.
Technical Outlook: Technically, TVRD is in a downtrend. The price is currently testing key support at $2.75. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 36.4% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $8.29 (+452.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, TVRD is in a downtrend. The price is currently testing key support at $2.75. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 36.4% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $8.29 (+452.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$2.42 -
$3.44
Company Quality Score
54/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
77.4%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-36.4%)
- BULLISH: Trading 452.4% below Wall St target ($8.29)
- WARNING: Recommendation downgraded due to -43.0% 5-day decline - wait for stabilization
Trading Range Analysis
30-Day Trading Range
$2.42 -
$3.44
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$2.75
Resistance Level
$3.57
Current Trend
Downtrend
Technical data as of
Jun 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-0.52
Wall Street Target
$8.29
(+452.4%)
Share & Embed Analysis
Last updated: June 27, 2026 5:10 AM ET
Data refreshes hourly during market hours. Next update: 6:10 AM
Data refreshes hourly during market hours. Next update: 6:10 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is TVRD showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$27 | 58 HOLD |
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$412 | 53 HOLD |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1022 | 59 HOLD |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 57 HOLD |
|
MRUS
Merus BV |
STRONG BUY
17 analysts |
$97 | 55 HOLD |